Micregen
Cell-free stem cell secretome therapies in preclinical development, starting with a treatment for premature-infant NEC
Highlights
- New on EvolcAdded 2026-10-30
About Micregen
Micregen is a UK company developing Secretomix®, a cell-free therapeutic platform built from substances released by stem cells rather than from the cells themselves. Its lead candidate, MRG1061, is designed for necrotising enterocolitis (NEC) in premature infants and has shown a statistically significant reduction in NEC lesion severity in preclinical models.
The company is in the advanced preclinical phase and has developed proprietary GMP cell banks and manufacturing partners for clinical-grade material. Its next steps are clinical-grade manufacture, GLP safety and toxicology work, a CTA submission to the MHRA and a first-in-human trial. Micregen is seeking investment for this step and plans to license the platform to pharma partners once initial human safety and efficacy data are available. Longevity applications are held separately under Anageria™.
Micregen was founded in 2015 and builds on about twenty years of academic stem cell secretome research. It is headquartered in Bolton and has a commercial office at Alderley Park, Cheshire. It is not currently advertising open roles.
Product: Secretomix®, a cell-free therapeutic platform based on stem cell secretome; lead candidate MRG1061 for necrotising enterocolitis.
Jobs at Micregen
Leadership
- Ketan Patel · Professor of Regenerative Medicine and Head of Molecular & Cellular Medicine, University of Reading.Source: company website
- Paolo De Coppi · Consultant Paediatric Surgeon at Great Ormond Street Hospital and Head of Stem Cells & Regenerative Medicine at the…Source: company website
- Rob Mitchell · Director of R&D & Co-FounderSource: company website
- Barry Sharples · Founder & Chief Executive.Source: company website
More biotech & pharma companies
Microbiotica
Clinical-stage biopharma developing microbiome-based live biotherapeutics for melanoma and ulcerative colitis patientsNew on EvolcMicropharm
Develops and manufactures polyclonal antibody medicines, including antivenoms, for healthcare marketsNew on EvolcMidland Pharmaceuticals
Clinical-stage therapeutics for spinal cord injury and ischemic stroke patientsYoung companyNew on EvolcMission Therapeutics
Develops small-molecule deubiquitylating enzyme (DUB) inhibitors for Parkinson's and other serious diseases, alone and with pharma partnersNew on EvolcMoolec Science
Produces animal proteins and plant-based ingredients in crops such as soybean and safflower for food companies worldwideNew on EvolcMyricx Pharma
Develops antibody-drug conjugate cancer therapies using payloads based on N-myristoyltransferase inhibitorsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Complianz
- Google Analytics 4
- Google Universal Analytics
- Google reCAPTCHA
- LiteSpeed
- PHP
- WordPress
- jQuery